Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Idiopathic Inflammatory MyopathiesANCA-Associated Vasculitis

Interventions

DRUG

RD06-04 Cell Injection Infusion

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Peking University People's Hospital

OTHER